Genevector Completes Tens of Millions RMB Financing to Accelerate Development of AAV Gene Therapies

Recently, Chengdu Jinweike Biotechnology Co., Ltd. (hereinafter referred to as "Jinweike") announced the completion of a multi-million yuan staged financing., this round of financing was jointly invested by Wuhan East Lake High Technology Equity Investment Management Co., Ltd. (referred to as "East Lake Investment") and SICHUANVENTURECAPITAL.After obtaining this round of financing, Jinweike Biotechnology will accelerate the clinical transformation and commercialization process of the AAV gene therapy pipeline, bringing hope of a cure to patients with genetic diseases!

Jinweike Biotechnology has established a technology platform centered on AAV capsid modification, gene expression cassette design, large gene delivery, and gene editing. Its gene therapy drug development capabilities and AAV preparation technology are among the leading levels in China.

The product pipeline is laid out in fields such as ophthalmic diseases, neuromuscular diseases, and genetic metabolic diseases. The first pipeline project, JWK001, has been approved for registration-based clinical trials and has entered Phase I/II clinical research. Additionally, several other pipelines under development have entered the IIT clinical research stage.

Jinweike Biotechnology's innovative world-first two-plasmid production process significantly reduces manufacturing costs, enhancing the accessibility of gene therapies. The company’s AAV gene therapy products have completed clinical studies involving over 170 patients, demonstrating excellent safety and efficacy data.

As the investor of this round of financing, Wuhan East Lake High Technology Equity Investment Management Co., Ltd., the industrial investment platform of Wuhan East Lake High Technology Group, focuses on high-tech industry clusters, concentrating on the biomedicine and intelligent manufacturing sectors to empower high-tech industries.Wuhan East Lake High Technology Equity Investment Management Co., Ltd. supports enterprise development through funds and direct investments, promoting the deep integration of capital and industry. It currently manages six industrial funds covering startups, growth-stage companies, and mature enterprises, focusing on value investing in high-quality businesses while providing value-added services. Over the past four years, it has invested in more than 30 companies, significantly enhancing the team's capabilities in investment management, capital operations, and investment banking, gaining recognition from external institutions.

Liao Tong, General Manager of Wuhan East Lake High Technology Equity Investment Management Co.,Ltd.As an existing shareholder of Jinweike Biotechnology,The reason for continued support of the company this time is the recognition of its ongoing innovative technology development capabilities in the AAV gene therapy field, which have been validated in clinical settings. The pipeline products have demonstrated excellent safety and efficacy in clinical trials, with some pipelines showing leadership and technical advantages on a global scale.We will continue to support the growth and development of Jinweike Biotechnology, further assisting Jinweike in achieving greater breakthroughs in the field of AAV gene therapy innovative drugs, and providing patients with more and better treatment options.

As the investor of this round of financing, SICHUANVENTURECAPITAL, a professional institution under the Sichuan Industrial Revitalization Fund Group engaged in equity investment and management, covers key industry sectors such as biomedicine, electronic information, and high-end intelligent manufacturing.SICHUANVENTURECAPITAL has successively established six regional sub-funds in the Sichuan Province Full Innovation Zone, China (Mianyang) Science and Technology City, Sichuan Free Trade Zone, and Southern Sichuan Economic Zone. It has also jointly initiated the establishment of eight industry sub-funds and four special sub-funds with top domestic investment institutions, managing a capital scale of nearly 10 billion yuan. This has preliminarily formed an investment and service network that deeply cultivates Sichuan and radiates across China.

Yu Yan, General Manager of the Fourth Investment Department of SICHUANVENTURECAPITALChengdu Jinweike Biotechnology Co., Ltd. has established a complete technical chain for AAV gene therapy drugs, and its innovative two-plasmid production process helps significantly reduce production costs.SICHUANVENTURECAPITAL has high confidence in the team capabilities and technology platform of Jinweike Biotechnology. We are pleased to invest in Chengdu Jinweike Biotechnology Co., Ltd. at this stage and look forward to the company continuously developing Best in class and First in class gene therapy drugs to address unmet clinical needs, benefiting a wide range of patients in the future.

Chen Lijing, Vice General Manager and Financing Director of Jinweike BiotechnologyStated: We are very pleased that Jinweike Biotechnology has gained the recognition and support of both new and existing investors. As a professional AAV gene therapy new drug R&D enterprise, Jinweike Biotechnology has always adhered to the concept of underlying technological innovation and product iteration upgrades. In the future, we will continue to rely on our core key technology platforms to comprehensively advance the progress of our product pipelines, accelerate the clinical transformation and industrialization process of our products, and look forward to bringing better treatment options to patients in China and around the world.

Yang Yang, Co-founder and CEO of Jinweike BiotechnologyStated: "We are highly honored to gain the favor and support of investment institutions. This not only affirms the efforts made by the Jinweike team in the past but also represents an expectation for future development. With the boost from this new round of financing, we hope to accelerate the R&D and industrialization of Jinweike's products, creating gene therapies that are affordable and effective for patients, benefiting more patients."